O ver the last several years, the number and severity of acute rejection episodes in kidney transplantation, have been reduced and short-term graft survival has greatly improved (1) . However, a similar improvement in long-term graft survival has not been observed and posttransplant complications remain common (1) . Among these, new-onset diabetes mellitus after transplantation (NODM) is a recognized complication associated with reduction in both graft and patient survival (2) . The reported incidence of NODM ranges from 4 -20%. The wide variability may reflect different diagnostic criteria for NODM, type of transplant, immunosuppression regimens, donor and recipient characteristics, and duration of follow-up (2) (3) (4) .
Since June 30, 2004, the Organ Procurement and Transplant Network/United Network for Organ Sharing (OPTN/UNOS) has been collecting data on the presence of diabetes via recipient follow-up forms. Using these data, we evaluated adult primary renal transplant recipients to identify risk factors associated with the development of NODM.
MATERIALS AND METHODS
Our study population was restricted to nondiabetic adult patients (age Ͼ20 years) who received their first kidney transplants alone between January 2004 and December 2005 with at least one follow-up report. A total of 15,309 adult kidney transplants alone were identified in the OPTN/UNOS database as of March 23, 2006. Among these, 1,581 patients developed NODM during the follow-up period.
Statistical Analysis
Baseline recipient, donor, and transplant factors according to the presence of NODM are compared using the chi-square test. Survival rate was estimated using the KaplanMeier product limit method. The log-rank test was used for comparison of the survival curves. For diabetes mellitus (DM)-free survival, primary endpoint was the time to diagnosis of NODM as a time-varying event: P(TϾt)ϭS(t) where P is the probability of a patient whose graft is functioning through time (T) without the development of NODM (t) and S is the survival function. Other events such as patient death, graft loss, and lost to follow-up were censored in DM-free survival analysis. Univariate and multivariate DM-free survival analyses were performed using Cox proportional hazard model. 
RESULTS
A total of 15,309 adult patients received a kidney transplant between January 2004 and December 2005 and, among them, 1,581 developed NODM. The prevalence of NODM according to recipient, donor, and transplant variables are listed in Table 1 . Table 2 shows unadjusted and adjusted relative risks for developing NODM. Statistically significant risk factors in univariate analyses were included in multivariate analysis. After adjusting for potential confounding variables using multivariate analysis, factors that highly correlated with the development of NODM included older age (PϽ0.001), hypertension prior to transplant (PϽ0.001), black race (PϽ0.001), BMI Ͼ30 (PϽ0.001), HCV antibody positivity in the recipient (PϽ0.001), tacrolimus use vs. other immunosuppressant (PϽ0.001), whereas alemtuzumab induction therapy was associated with a decreased risk of NODM. However, extended criteria donor, number of HLA mismatches, and type of donor were no longer associated with an increased relative risk for the development of NODM after adjusting for other factors.
DM-free survival curves according to two major risk factors for developing NODM are shown in Figures 1 and 2 . Decreased DM-free survival rate with increasing BMI can be seen in Figure 1 . Unadjusted DM-free survival rates at 12 and 24 months were: 91.1% and 85.2% for BMI Ͻ25; 88.2% and 76.5% BMI 25-30; and 84.4% & 74.1% BMI Ͼ30 (PϽ0.001). The effect of obesity continued to be significant after adjusting for other risk factors as shown in Fig. 2 ). The effect of tacrolimus use continued to be significant after adjusting for other risk factors ( 
DISCUSSION
NODM is a common and important complication after renal transplantation (5) . A recent meta-analysis of observational studies and randomized controlled trials reported that the incidence of NODM in the first year after kidney transplantation varied from 2 to 50% (4). The differences in reported rates of NODM may in part be due to the varying definitions of diabetes, the duration of follow up, the type and dose of immunosuppressant, and the prevalence of predisposing risk factors (3) . A recent study done by Kasiske et al. evaluated many of these risk factors using the United States Renal Data System/Medicare database (2) . Although this was the largest study of its kind, only about 20% of transplant patients in the United States were included in the analysis. It is recognized that Medicare beneficiaries have a higher prevalence of risk factors for NODM compared with the nonMedicare primary population. The overall incidence of NODM in our study was 10% during the mean follow-up of 10 months compared to 16.0% at one year in the Medicare study. This difference is due to the different baseline characteristics among these two groups rather than the type of insurance as confirmed by the multivariate result showing that Medicare insurance is not an independent risk factor for NODM (data not shown).
Our study confirmed several risk factors for NODM that were previously reported in clinical trials and retrospec- tive studies of registry data. Of all risk factors, only obesity, hepatitis C infection, and the type of immunosuppressive medications used are potentially modifiable. Obesity and hepatitis C infection are known factors associated with inferior transplant outcomes (6, 7) . Whether or not, modifying these "modifiable risk factors" would indeed result in a decrease in the incidence of NODM is not known. The type of transplant was shown to be a risk factor in univariate analysis but was not an independent risk factor in the multivariate analysis. This may be due to older recipients being more likely to receive extended donor criteria kidney compared to younger recipients. Recently, two groups have published the association between polycystic kidney disease and NODM (8, 9) . However, in this study, we did not find this association (result not shown). The relative risk of NODM was 49% greater in patients treated with tacrolimus compared those who were not discharged with tacrolimus. This corresponded to 2% difference in prevalence among the two groups. This finding is consistent with those of randomized controlled trials, where the incidence of NODM is consistently higher among patients treated with tacrolimus compared to cyclosporine (10) . It was previously noted that the high incidence of NODM in tacrolimus treated recipients in early clinical trials may be in part due to the high targeted trough levels. Our study was performed using a very recent cohort of kidney transplant recipients. Even in the mid-2000s, when the target level of tacrolimus is lower than previously targeted levels, the risk of developing NODM from tacrolimus has been relatively unchanged. In contrast to the effects of tacrolimus, the use of alemtuzumab was associated with a 48% lower 
